Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study.
We report a phase I/II study of weekly concurrent carboplatin and radiotherapy in patients with nasopharyngeal carcinoma (M0 stage). Of 47 patients registered, 45 completed the treatment course. Twenty-six (55%) (95% CI, 41-69%) patients experienced > or =grade 3 acute toxicity (RTOG). Five (11%) (95% CI, 2-20%) patients experienced > or =grade 3 chronic toxicity. This regimen appears to have acceptable toxicity compared to the experimental arm of Phase III Intergroup Study 0099, but progression-free and overall survival are probably inferior. At present, there is no data to suggest that carboplatin can replace cisplatin for concurrent chemoradiation for NPC.
Parliament
M
M
Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
Jha
N
N
Rapp
E
E
Smith
C
C
MacKinnon
J
J
Nabholtz
J M
JM
Hanson
J
J
Reiman
T
T
Mackey
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016470:Bacteremia / Q000209:etiology; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003389:Cranial Nerve Diseases / Q000209:etiology; D018450:Disease Progression; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009325:Nausea / Q000209:etiology; D009503:Neutropenia / Q000209:etiology; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D013223:Statistics as Topic; D015996:Survival Rate; D016896:Treatment Outcome; D014839:Vomiting / Q000209:etiology
D000970:Antineoplastic Agents; D016190:Carboplatin